 Hey guys, how you doing? This is rich from rich TV live and you know I always tell you guys to invest in the best because the best is blessed I got to give it out to Dylan Fraser man. He brought me this pic and I have a feeling it's gonna blow allergen pharmaceuticals at 15 cents up 66% on Friday and They've got some big news guys symbol in America a GNP F symbol in Canada a GN both the American and Canadian symbol exploded on Friday and the symbol in Frankfurt, Germany a GW another potential big winner Another big winner. It's true. Check this out. Look at the big news. This came out after market after market on Friday allergen Algernon pharmaceuticals Inc a GN in Canada a GW in Frankfurt a GNP F in America a clinical stage pharmaceutical development company is pleased to announce it will set aside some of its NP 120 ifan pro-dill drug supply from its planned phase two study of idopathic fibrosis and chronic cough to make it available on a compassionate use basis to physicians and their patients with the most serious cases of Coronavirus You know as soon as you put that word in a press release You know that people are going to pay attention The decision was made based on the results of an independent study of ifan pro-dill Which showed a 40% improvement in mortality and significantly reduced acute lung injury ALI in a recent h5n1 animal study h5n1 is one of the most lethal form of influenza known with a 53% mortality rate Since ifan pro-dill is an already approved drug with a known safety history It can be safely administered to patients without additional preclinical testing I think this is huge news is breaking news If we see a similar response in coronavirus patients as seen in the h5n1 animal study a far more lethal form of Influenza we believe that patient outcomes should be significantly improved said Christopher J. Morneau CEO of Algernon Algernon Welcomes contact from the health organizations and physicians globally to learn more about NP-120 ifan pro-dill This is huge news management believe that the NP-120 ifan pro-dill is a possible treatment for COVID-19 coronavirus is based on historical animal studies and not on human trials You only find these out first here on rich TV live This is where you get the picks folks you get the picks first from your boy at rich TV live It's true. We bring you the winners first not second not third not fifth not fifty fifth First it's true. What do you think about? What do you think about this stock? Algernon Pharmaceuticals NP-120 ifan pro-dill is an N Methodal D aspirate NDMA receptor glutamate receptor antagonist specifically targeting the NMDA dash type subunit to be glue to NB ifan pro-dill also exhibits Anganist activity for the Sigma one receptor a chair-of-phone protein up-regulated during endoplasmic reticulum stress although the anti-fibro fibrotic activity of ifan pro-dill in IPF is not known Recent studies have suggested a link between both receptors and pathways associated with fibrosis Glutamate GLU is the main excitatory Neurotransmitter which acts as glutamate receptors in the central nervous system otherwise known as CNS, but over activation of these receptors can cause several damages to neural cells including death Recent studies show that the glutamate agonist N Methadol D aspirate NMDA can trigger acute lung injury ALI ALI is direct and indirect injury to alveolar epithelial cells and capillary and dothanil cell causing diffuse pulmonary interstitle and alveolar endema and acute hypoxic respiratory respiration failure. ALI is characterized by reduced lung volume and compliance and imbalance of the ventilation perfusion ratio inducing hyporexamia and respiratory distress and its severe stage oxygen index 200 known as acute respiratory distress syndrome or ARDS N-120 ifan pro-dill brand name Sirocow was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders the drug is Genericized and sold in Japan Algernon has Failed filed with new intellectual property rights for NP-120 Ifan pro-dill for the treatment of respiratory disease. This is absolutely huge We're talking about a 12 cent stock in America 15 cents in Canada Nobody even knows and these guys could potentially be helping the entire world Algernon pharmaceuticals is a clinical stage pharmaceutical development company Focused on advancing its lead compounds for non-alcoholic Steetho Hepatitis or otherwise known as NASH Nash chronic kidney disease CKD Inflator inflammatory bowel disease IBD and idopathic pulmonary fibrosis IPF and chronic cough. This is breaking news Thank you Dylan Fraser for bringing this news first. This is your boy, Richard Mr. Live bringing you the news a new deadly coronavirus potential explosive pick Algernon pharmaceuticals a GN in Canada and in America a GNPF and in Frankfurt, Germany a GW if you're not winning you're not watching this your boy Richard mr. Live and I'm out peace